Overall survival · Adult patients with myelodysplastic syndromes and thrombocytopenia
1 finding from 1 review
Mortality during study · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics showed no clear difference in mortality during study compared with placebo (low certainty).
1 finding from 1 review
Transformation to AML · Adult patients with myelodysplastic syndromes and thrombocytopenia
It is very uncertain whether thrombopoietin mimetics changes transformation to AML compared with placebo (very low certainty).
1 finding from 1 review
Incidence of bleeding events · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics probably leads to lower incidence of bleeding events compared with placebo (moderate certainty).
1 finding from 1 review
Blood transfusion requirements · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics showed no clear difference in transfusion requirement compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life · Adult patients with myelodysplastic syndromes and thrombocytopenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics showed no clear difference in all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia
It is very uncertain whether thrombopoietin mimetics changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Number of participants with at least 1 bleeding episode · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
It is very uncertain whether thrombopoietin mimetics changes number of participants with at least 1 bleeding episode compared with placebo or standard care (very low certainty).
1 finding from 1 review
Number of participants with severe or life‐threatening bleeding · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
It is very uncertain whether thrombopoietin mimetics changes number of participants with severe or life‐threatening bleeding compared with placebo or standard care (very low certainty).
1 finding from 1 review
Number of days on which bleeding occurred ‐ not measured · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to first bleeding episode (days) · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
1 finding from 1 review
no estimate extracted
4 participants
GRADE not reported
Number of platelet transfusions per participant up to 30 days from study entry · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
1 finding from 1 review
Thromboembolic events · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
1 finding from 1 review
Quality of life ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found